Kenvue Inc. (NYSE:KVUE) Shares Acquired by AlphaStar Capital Management LLC

AlphaStar Capital Management LLC boosted its stake in Kenvue Inc. (NYSE:KVUE) by 102.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 22,805 shares of the company’s stock after acquiring an additional 11,549 shares during the quarter. AlphaStar Capital Management LLC’s holdings in Kenvue were worth $487,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AMF Tjanstepension AB increased its stake in Kenvue by 187.3% during the 3rd quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock worth $2,787,000 after buying an additional 78,540 shares in the last quarter. Mather Group LLC. boosted its stake in shares of Kenvue by 62.0% in the third quarter. Mather Group LLC. now owns 6,857 shares of the company’s stock worth $159,000 after acquiring an additional 2,625 shares during the last quarter. Atomi Financial Group Inc. purchased a new stake in shares of Kenvue during the third quarter worth approximately $212,000. Livforsakringsbolaget Skandia Omsesidigt raised its stake in Kenvue by 291.9% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 16,624 shares of the company’s stock valued at $385,000 after purchasing an additional 12,382 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its stake in Kenvue by 371.7% in the 3rd quarter. Exchange Traded Concepts LLC now owns 29,887 shares of the company’s stock valued at $691,000 after purchasing an additional 23,551 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE stock opened at $20.23 on Monday. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market cap of $38.79 billion, a price-to-earnings ratio of 38.17, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45. The business has a fifty day moving average of $21.54 and a two-hundred day moving average of $21.97.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, research analysts anticipate that Kenvue Inc. will post 1.05 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 4.05%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is 154.72%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on KVUE. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Barclays dropped their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Bank of America boosted their target price on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Finally, Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and cut their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.